- Earlier in June 2026, Agilent Technologies announced FDA approval to expand use of its PD-L1 IHC 22C3 pharmDx diagnostic on the Dako Omnis platform across multiple additional cancer types, while also revealing a collaboration with OpenAI and Boston Consulting Group to accelerate artificial intelligence deployment in its instruments, software, and services.
- This combination of broader companion diagnostic use for KEYTRUDA and a company-wide push into applied AI could reshape how Agilent supports oncologists and lab customers across both testing workflows and product development.
- We’ll now examine how Agilent’s new AI collaboration with OpenAI and Boston Consulting Group may influence its existing investment narrative.
Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
Agilent Technologies Investment Narrative Recap
To own Agilent, you generally need to believe in steady demand for life science tools, growing high-margin recurring revenues, and disciplined cost control despite tariff and supply chain pressures. The latest PD-L1 expansion and AI collaboration look directionally positive for diagnostics and workflow efficiency, but do not materially change the near term focus on offsetting tariff-driven cost inflation and managing competitive intensity in core instruments.
Among recent announcements, the FDA’s expanded approval of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform stands out, because it reinforces Agilent’s role in KEYTRUDA-related testing across more tumor types. That kind of clinically anchored diagnostic footprint can matter for the company’s core catalyst of driving higher recurring test volumes, even as broader risks around tariffs, funding pressure in Academia & Government, and capital replacement cycles remain in view.
Yet investors should still be aware that rising tariff driven costs and supply chain complexity could...
Read the full narrative on Agilent Technologies (it's free!)
Agilent Technologies' narrative projects $8.8 billion revenue and $2.1 billion earnings by 2029.
Uncover how Agilent Technologies' forecasts yield a $161.00 fair value, a 23% upside to its current price.
Exploring Other Perspectives
Four members of the Simply Wall St Community currently place Agilent’s fair value between US$150.54 and US$166.26, illustrating how far personal models can differ. Set this against the risk that higher tariffs and supply chain complexity may keep pressuring margins, and you have several distinct viewpoints on how resilient Agilent’s earnings profile really is, which are worth comparing before you decide where you stand.
Explore 4 other fair value estimates on Agilent Technologies - why the stock might be worth as much as 27% more than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Agilent Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.
Searching For A Fresh Perspective?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
- Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com